5395232026-07-012026-09-305395232026-09-305395232026-03-315395232026-04-012026-09-305395232026-07-012026-09-30in-capmkt:OtherExpenses1Member5395232026-04-012026-09-30in-capmkt:OtherExpenses1Member5395232026-09-30OtherNoncurrentFinancialAssetsDomain15395232026-09-30OtherNoncurrentAssetsDomain15395232026-09-30OtherCurrentFinancialAssetsDomain15395232026-09-30OtherCurrentAssetsDomain15395232026-09-30OtherNoncurrentFinancialLiabilitiesDomain15395232026-09-30OtherNoncurrentLiabilitiesDomain15395232026-09-30OtherCurrentFinancialLiabilitiesDomain15395232026-09-30OtherCurrentLiabilitiesDomain15395232026-07-012026-09-30in-capmkt:ReportableSegments1Member5395232026-07-012026-09-30in-capmkt:ReportableSegments2Member5395232026-07-012026-09-30in-capmkt:ReportableSegments3Member5395232026-04-012026-09-30in-capmkt:ReportableSegments1Member5395232026-04-012026-09-30in-capmkt:ReportableSegments2Member5395232026-04-012026-09-30in-capmkt:ReportableSegments3Member5395232026-07-012026-09-30in-capmkt:ReportableSegments1Member5395232026-07-012026-09-30in-capmkt:ReportableSegments2Member5395232026-07-012026-09-30in-capmkt:ReportableSegments3Member5395232026-04-012026-09-30in-capmkt:ReportableSegments1Member5395232026-04-012026-09-30in-capmkt:ReportableSegments2Member5395232026-04-012026-09-30in-capmkt:ReportableSegments3Member5395232026-07-012026-09-30in-capmkt:ReportableSegments1Member5395232026-09-30in-capmkt:ReportableSegments1Member5395232026-07-012026-09-30in-capmkt:ReportableSegments2Member5395232026-09-30in-capmkt:ReportableSegments2Member5395232026-07-012026-09-30in-capmkt:ReportableSegments3Member5395232026-09-30in-capmkt:ReportableSegments3Member5395232026-07-012026-09-30in-capmkt:ReportableSegments1Member5395232026-09-30in-capmkt:ReportableSegments1Member5395232026-07-012026-09-30in-capmkt:ReportableSegments2Member5395232026-09-30in-capmkt:ReportableSegments2Member5395232026-07-012026-09-30in-capmkt:ReportableSegments3Member5395232026-09-30in-capmkt:ReportableSegments3Member5395232026-07-012026-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15395232026-04-012026-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss1iso4217:INRxbrli:pureiso4217:INRxbrli:shares539523ALKEMNOTLISTEDINE540L01014ALKEM LABORATORIES LIMITEDMain BoardEquity2026-04-012027-03-312026-11-122026-11-04INRMillionsQuarterlySecond quarterMulti segment2026-11-1211:30:002026-11-1213:40:00trueCash Flow IndirectNot applicable2026-07-012026-09-30UnauditedConsolidated45519900000134210000046862000000108303000004688300000-571100000896520000057670000013708000001135530000037215500000964650000035000000099965000004053400000-734300000331910000006677400000000-61000006671300000-11590000065554000006753400000-821000006676400000-121000000239100000256.4856.480056.4856.480001. The above consolidated financial results are prepared in accordance with the lndian Accounting Standards prescribed under section 133 of the Companies Act, 2013 and are in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended). The Consolidated Financial results are prepared in accordance with Ind AS 110 'Consolidated Financial Statements'. <br /> <br /> 2. The above consolidated financial results of the Group were reviewed and recommended by the Audit Committee on 11 November 2026 and subsequently approved by the Board of Directors at its meeting held on 12 November 2026. The auditors have issued an unmodified review report on the financial results for the quarter and six months ended 30 September 2026. <br /> <br /> 3. Exceptional item includes: <br /> <br /> a) Exceptional item for the quarter and six months ended 30 September 2026 represents recovery of Rs. 350 million against investment made, which was impaired during the quarter and year ended 31 March 2026. <br /> <br /> b) Exceptional item amounting to Rs.142.9 million for the six months ended 30 September 2025 is on account of gain on sale of Indore facility which was impaired earlier. <br /> <br /> c) Exceptional items amounting to Rs.1,748.3 million for the year ended 31 March 2026 mainly includes <br /> - Impact of labour code of Rs. 1,130.6 million towards gratuity and leave encashment for past service cost; <br /> - Impairment of real estate investment made of Rs.747 million; <br /> - Gain on sale of Indore facility of Rs.142.9 million. <br /> <br /> 4. During the quarter and year ended 31 March 2026, pursuant to the amendments introduced under the Finance Act, 2026, interalia allowing set off of available MAT credit under new tax regime (Section 115BAA of the Income-tax Act, 1961), the Parent Company and one of its Indian subsidiary; had decided to opt for the new tax regime from financial year 2026 – 27. Consequently, deferred tax had been recognised at the substantially enacted rate for the year ended 31 March 2026. Subsequently in the current period, the tax expense has been recognized based on the enacted tax rates applicable under the new regime. <br /> <br /> 5. During the quarter ended 30 September 2026, Alkem Medtech Private Limited (AMPL), a wholly owned subsidiary of the Parent Company, completed the acquisition of a 55% equity stake in Occlutech Holding AG ("Occlutech") pursuant to the Share Purchase Agreement (SPA). The acquisition of controlling interest was completed on 16 July 2026 for a fair value consideration of EUR 97.8 million (approx Rs. 10,797.6 million) (comprising cash consideration of Rs. 8,778.3 million and deferred consideration of Rs. 2,019.3 million), subject to adjustments in accordance with the terms of the SPA. <br /> <br /> Accordingly, Occlutech became a subsidiary of the Group with effect from the acquisition date, and its financial results have been consolidated from 16 July 2026. Consequently, the results for the current period are not comparable with those of the corresponding previous periods. <br /> <br /> The acquisition has been accounted for in accordance with Ind AS 103, Business Combinations. Based on the provisional Purchase Price Allocation (PPA), identifiable assets and liabilities acquired amounted to Rs. 16,047.8 million and Rs. 9,208.6 million (including deferred tax liability of Rs. 1,724.0 million) respectively. The acquisition resulted in recognition of goodwill of Rs. 7,036.0 million. The PPA will be finalised within the measurement period permitted under Ind AS 103, and any resulting adjustments will be recognized retrospectively from the acquisition date.2026-04-012026-09-30UnauditedConsolidated82921400000286960000085791000000199305000008348200000-13185000001705420000010429000002372700000209946000006842460000017366400000350000000177164000006374000000-5499000005824100000011892300000000-1120000011881100000-871000001179400000011953000000-7190000011905000000-111000000239100000299.9799.970099.9799.97000Other Expenses11355300000Other Expenses209946000003154120000016079000000122102000001360760000014219000000336900000118344000000072498000001908420000017471800000265640000099938100000352527000008559700000337005000004084300000209100000090900000357892000008431560000083690000010253100000130658300000002305964000002391000001484130000001486521000008237900000156890000000103346000000009668700000200033000004416400000203390000001619000002661550000082960000001313700000197213000002103500000010054500000393855000003498900000219590000020106000000470909000000073706400000230596400000Other non-current financial assets7249800000Other non-current assets2656400000Other current financial assets35789200000Other current assets10253100000Other non-current financial liabilities9668700000Other non-current liabilities161900000Other current financial liabilities10054500000Other current liabilities3498900000Pharmaceuticals43479200000Biotech1297900000MedTech1331400000Pharmaceuticals80012400000Biotech2496500000MedTech140790000046108500000839168000005886000009954000004551990000082921400000Pharmaceuticals10518800000Biotech-1141400000MedTech-496300000Pharmaceuticals18212700000Biotech-2054200000MedTech-6188000008881100000155397000005767000001042900000-1342100000-2869600000964650000017366400000Pharmaceuticals101889500000Biotech16884000000MedTech2486340000014363690000086959600000230596500000Pharmaceuticals41535500000Biotech6164900000MedTech3330700000510311000002267530000073706400000Pursuant to the acquisition of a controlling interest in Occlutech Holding AG in July 2026, the Group reassessed its reportable operating segments following changes in the information being reviewed by the Chief Operating Decision Maker (CODM). Based on the revised internal reporting, the Group has identified Pharmaceuticals, Biotech and MedTech as its reportable operating segments. <br /> <br /> Following the change in the composition of the Group’s reportable operating segments, comparative segment information for the prior periods presented has been prepared on the basis of the current reportable segment structure to facilitate comparability. Accordingly, segment information has been presented in accordance with the requirements of Ind AS 108. <br /> <br /> 'The Group’s treasury operations are managed centrally. Accordingly, cash and bank balances, investments, bank deposits, deposits with financial institutions, borrowings from banks and financial institutions, other related assets and liabilities and resulting income/expense have been presented as unallocated assets, liabilities, income and expense. Further, all tax assets and liabilities have also been presented as unallocated assets and liabilities.1042900000-725300000-33391000000-108060000000003679000000002372700000018000000000863000007000002160500000-7200000-31000000000-1374000000-35940000001412240000000036766000000104458000000808040000000000013590000032089000000000000000041794200000361406000000000700000171600000000-378310000000000000947220000012364800000444900000124820000087750000001024000000-44392000002223500000282000002251700000-3421400000-1169700000Remeasurements of defined benefit plans-29000000-29000000Remeasurements of defined benefit plans-54400000-54400000-5400000-138000009230000046500000-115900000-87100000